Innoviva, Inc. (INVA)

Innoviva Inc. (INVA) is a pharmaceutical company that focuses on the development, commercialization, and financial management of bio-pharmaceuticals. The company is engaged in the development and commercialization of therapeutics for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory diseases. INVA has a portfolio of respiratory assets partnered with GlaxoSmithKline plc, including RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA, which are marketed by GSK. The company's business model is based on receiving royalties from the sales of these products. INVA was founded in 1996 and is headquartered in Brisbane, California.